Atrial Fibrillation Symposium 2023 gave an insight into new technologies for atrial fibrillation, atrial fibrillation ablation and left atrial appendage closure. In this touchCARDIO interview, we speak with Prof. Luigi Di Biase (Albert Einstein College of Medicine, Montefiore Health System, New York, NY, USA) to discuss his highlights from the Atrial Fibrillation Symposium, 2–4 February 2023.
Question:Â
What are the hot topics and new research you’re most interested in from the AF Symposium 2023? (0:16)
Disclosures: Luigi Di Biase is a consultant for Biosense Webster, Rhythm Management and Stereoataxi, and has received speaker honoraria/travel funding from Atricure, Baylis, Biosense Webster, Biotronik, Boston Scientific, Medtronic, St. Jude Medical (now Abbott) and Zoll.
Support: Interview and filming supported by Touch Medical Media. Interview conducted by Danielle Crosby.
Filmed as a highlight of AFS 2023
Access more content on Atrial Fibrillation here
Transcript:
Hello I am Professor Luigi Di Biase from the Albert Einstein College of Medicine at Montefiore Health System in New York.
What are the hot topics and new research you’re most interested in from the AF Symposium 2023? (0:16)
The AFib Symposium 2023, as usual, has given us a comprehensive review of all new technology that are happening to atrial fibrillation in general, and atrial fibrillation ablation and left appendage occlusion. What I have to say is that the development of a new energy source for atrial fibrillation ablation, termed pulsed-field ablation, PFA, which is a non-thermal energy source, is the most attractive thing that I think everybody was very excited about. We have moved from bench to clinical trials in Europe and in the US and I feel this new energy source will really change the way we treat our patients for atrial fibrillation.
